Company Overview and News

 
Strength Seen in Iteris (ITI): Stock Moves 8.2% Higher

2016-01-07 zacks
Iteris, Inc. (ITI) was a big mover last session, as the company saw its shares rise over 8% on the day.

 
Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

2016-01-04 247wallst
While aggressive investors love biotechnology, and the returns over the years for the top stocks have been outstanding, 2016 could be a wild-card, as the election cycle is going to keep drug pricing and health care costs front and center. Politicians looking for votes like nothing better than to find a scapegoat for bellicose populist rhetoric.

 
VANGUARD VALLEY FORGE FUNDS Form N-Q

2015-12-01 sec.gov
valleyforge_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-58431   Name of Registrant:   Vanguard Valley Forge Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

 
VANGUARD INDEX FUNDS Form N-Q

2015-12-01 sec.gov
index_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-02652   Name of Registrant:   Vanguard Index Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

 
Iteris' (ITI) CEO Joe Bergera on Q2 2016 Results - Earnings Call Transcript

2015-11-11 seekingalpha
Iteris, Inc. (NYSEMKT:ITI) Q2 2016 Earnings Conference Call November 10, 2015, 4:30 pm ET Executives Joe Bergera - President & CEO Andy Schmidt - CFO Analysts Jeff Van Sinderen - B. Riley Presenta

 
Soy Beans And Traffic Lights? Iteris's Risky Shift Into Agriculture

2015-07-25 seekingalpha
The company's traffic technology segment generates $5 million per year in cash.Connected and autonomous vehicles create future opportunity.ClearAg's is facing stiff competition, in a new industry, wit

 
Valuable Core, Outrageously Cheap Due To Doomed Adventures Of Just Fired CEO

2014-12-30 seekingalpha
Valuable Core Business: A co-leader at worst in the camera based traffic control market. Flir Systems paid $46m for co-leader Traficon in December 2012. Enjoys a stable pure profit royalty stream of $

 
Iteris' (ITI) CEO Abbas Mohaddes on Q1 2015 Results - Earnings Call Transcript

2014-10-17 seekingalpha
Iteris Inc. (NYSEMKT:ITI) Q1 2015 Earnings Conference Call October 16, 2014 4:30 PM ET Executives Abbas Mohaddes – President and Chief Executive Officer Craig Christensen – Chief Financial Officer (I

 
Today In SA PRO: Monday, September 8

2014-09-09 seekingalpha
Top Idea: Layne Christensen by BuyTheDip SellTheRip: Long / Micro-Cap / Heavy Construction / Contrarian / Lagging Market Sentiment / Sum of the Parts / 100% Upside Top Idea: Hutchinson Technology by T

 
Iteris' (ITI) CEO Abbas Mohaddes on Q4 2014 Results - Earnings Call Transcript

2014-09-03 seekingalpha
Iteris, Inc. (NYSEMKT:ITI) Q4 2014 Earnings Conference Call September 3, 2014 4:30 PM ET Executives Abbas Mohaddes – President and Chief Executive Officer Craig Christensen – Chief Financial Officer

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

14h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

14h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...